Enliven Therapeutics Stock (NASDAQ:ELVN)

Forecast Ownership Financials Chart

Previous Close

$18.77

52W Range

$13.30 - $25.37

50D Avg

$20.80

200D Avg

$20.01

Market Cap

$997.92M

Avg Vol (3M)

$590.25K

Beta

1.07

Div Yield

ELVN Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 12, 2020

Website

ELVN Performance

ELVN Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-104.55M	$-83.53M	$-38.79M
Net Income	$-89.02M	$-71.58M	$-37.75M
EBITDA	$-104.55M	$-81.93M	$-38.58M
Basic EPS	$-1.89	$-2.01	$-6.03
Diluted EPS	$-1.89	$-2.01	$-6.03

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
IMTX	Immatics N.V.
ATAI	Atai Beckley N.V
RLAY	Relay Therapeutics, Inc.
NKTR	Nektar Therapeutics
SANA	Sana Biotechnology, Inc.
SNDX	Syndax Pharmaceuticals, Inc.
ORIC	ORIC Pharmaceuticals, Inc.
PGEN	Precigen, Inc.
INBX	Inhibrx Biosciences, Inc.
DNTH	Dianthus Therapeutics, Inc.